Targeted Strategies for Today's Evolving Markets

MissionIR Blog

International Stem Cell Corp. (ISCO) Appoints Ms. Mahnaz Ebrahimi as CFO

Today before the opening bell, International Stem Cell Corp. announced that Mahnaz Ebrahimi will be taking over as the new chief financial officer, effective September 14, 2015. The prior CFO, Jay Novak, ended his employment in May.

Ms. Ebrahimi is a certified public accountant, a certified equity professional and a certified cash manager. She has more than 25 years of experience in financial management and accounting of growing research-driven companies in the life sciences, biotechnology, and pharmaceutical sectors. Most recently, she has been assisting several biotechnology and technology companies on accounting and SEC related matters in an expert consultancy capacity, including Flux Power Holdings, Polaris Pharmaceuticals and Ocera Therapeutics.

From 2010 until an acquisition took place in 2012, Ms. Ebrahimi served as director of Finance and Planning, as well as Treasury, of eBioscience. She also served as vice president of Finance and Administration and chief financial officer of Profil Institute for Clinical Research from 2003 to 2005. From 1989 to 2000, she served as director of Finance & Treasury and assistant controller of Agouron Pharmaceuticals, which became a subsidiary of Pfizer in 2000.

For those unfamiliar with International Stem Cell Corp., it is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and stem cell-based skin care products through its subsidiary Lifeline Skin Care.

For more information, visit

This entry was posted in International Stem Cell Corp. ISCO. Bookmark the permalink.

Comments are closed.